AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis
14 oct. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Two clinical trial sites activated in Turkey, with patient screening initiatedFollows activation of six clinical sites in Hungary and dosing of first eight patientsTopline data expected in Q2 2021 ...
AzurRx BioPharma CEO Issues Letter to Shareholders
07 oct. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference
15 sept. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Abstracts to Focus on: Results from Phase 2, Open-Label, Multicenter, 2x2 Cross-Over Trial to Assess Safety and Efficacy of MS1819 in Patients with Exocrine Pancreatic Insufficiency Due to Cystic...
AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)
31 août 2020 08h00 HE
|
AzurRx BioPharma, Inc.
NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
17 août 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Three clinical trial sites activated in Poland, with patient screening initiatedFollows activation of six clinical sites in the U.S. and dosing of first three patientsTopline data expected in Q1 2021 ...
AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
13 août 2020 08h00 HE
|
AzurRx BioPharma, Inc.
First three patients enrolled in dose escalation trial using delayed-release enteric capsulesTopline data expected in 1H 2021 NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc....
AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product
07 mai 2020 08h00 HE
|
AzurRx BioPharma, Inc.
NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit)
05 mai 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Received ~$2.52 million in aggregate CIR payments in 2020CIR to be used to fund on-going MS1819 Phase 2 clinical studies in Europe NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma,...
AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
30 avr. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
IRB protocol approval provides green-light to initiate trial at U.S. clinical sites NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”),...
AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites
29 avr. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
On track to initiate the OPTION 2 trial by the end of Q2 2020OPTION 2 trial to compare efficacy of standard of care to 2.2 and 4.4 gram doses of MS1819 in enteric capsulesTrial completion and top-line...